Management of patients with valvar heart diseases in 2008 - What has changed during recent decades?;Management von herzklappenpatienten 2008 - Was hat sich in den letzten drei jahrzehnten geändert?

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 50 SUPPL. 8, 2008, Pages

  Horstkotte, Dieter ^a   Piper, C ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Anticoagulation; Aortic valve stenosis; Heart valve replacement; Mitral regurgitation; Valvar heart diseases

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K;

ANTICOAGULATION; AORTA VALVE STENOSIS; COMORBIDITY; EARLY INTERVENTION; HEART EJECTION FRACTION; HEART VALVE REPLACEMENT; HUMAN; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; MORTALITY; PATIENT CARE; PERIOPERATIVE COMPLICATION; PREVALENCE; PROGNOSIS; REVIEW; TREATMENT INDICATION; VALVULAR HEART DISEASE;

EID: 57849097820     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1100962     Document Type: Review

References (25)

1. Antithrombotic Management after Heart Valve Replacement: Results and Consequences of the GELIA study. Proceedings of an International Symposium held on March 30-31, 2001 in Bad Oeynhausen, Germany. Eur Heart J Suppl 2001; 3, Suppl Q
2. Bonow RO, Carabello BA, Chatterjee K et al. ACC/AHA 2006 Guidelines for the Management of Patients with Valvular Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2006; 48: 1-148
3. Gummert JF, Funkat A, Beckmann A et al. Cardiac surgery in Germany during 2005. A report on behalf of the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surgeon 2006; 54: 362-371
4. Hering D, Piper C, Horstkotte D. Infuence of atypical symptoms and electrocardiographic signs of left ventricular hypertrophy or ST-segment/T-wave abnormalities on the natural history of otherwise asymptomatic adults with moderate to severe aortic stenosis: preliminary communication. J Heart Valve Dis 2004; 13: 182-187
5. Horstkotte D(Hrsg). Antithrombotische Therapie nach Herzklappenersatz. Z Kardiol 1998; 87,Suppl 4
6. Horstkotte D, Piper C, Wiemer M, Schultheiß HP. Management von Patienten mit Aortenklappenstenosen. Herz 1998; 23: 434-440
7. Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thrombosis and Thrombolysis 1998; 5: S19-S24
8. Huth C, Friedl A, Rost A for the GELIA Study Investigator Group. Intensity of oral anticoagulation after implantation of St.- Jude Medical aortic prosthesis: analysis of the GELIA Database (GELIA 4). Eur Heart J Suppl 2001; 3 (Suppl Q): Q33-Q38
9. Kalmar P, Irrgang E. Cardiac surgery in the Federal Republic of Germany during 1990. A report by the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surgeon 1991; 39: 167-169
10. Kalmar P, Irrgang E. Cardiac surgery in Germany during 1995. A report by the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surgeon 1996; 44: 161-164
11. Kafmar P, Irrgang E. Cardiac surgery in Germany during 2000. A report by the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surgeon 2000; 48: XXXIII-XXXVIII
12. Miche E, Bogunovic N, Fassbender D et al. Predictors of unsuccessful outcome after percutaneous mitral valvotomy including a new echocardiographic scoring system. J Heart Valve Dis 1996; 5: 430-35
13. Neumayer U, Schmidt HK, Fassbender D et al. Early (three-month) results of percutaneous mitral valvotomy with the Inoue balloon in 1,123 consecutive patients comparing various age groups. Am J Cardiol 2002; 90: 190-193
14. Piper C, Bergemann R, Schulte HD et al. Can progression of valvar aortic stenosis be predicted accurately? Ann Thorac Surg 2003; 76: 676-80
15. Piper C, Horstkotte D. State of the Art in Anticoagulation Management. J Heart Valve Dis 2004; 13 (Suppl 1): S76-S80
16. Piper C, Schultheiss HP, Akdemir D et al. Remodeling of the cardiac extracellular matrix differs between volume and pressure-overloaded ventricles and is specific for each heart valve lesion. J Heart Valve Dis 2003; 12: 592-600
17. Piper C, Wiemer M, Schultheiß HP, Horstkotte D. Sinnvolle Diagnostik und Therapieplanung bei organischer und relativer Mitralklappeninsuffizienz. Herz 1998; 23: 429-433
18. Preiss M, Bernet F, Zerkowski HR. Additional information from the GELIA database: analysis of benefit from self-management of oral anticoagulation (GELIA 6). Eur Heart J Suppl 2001; 3 (Suppl Q): Q50-Q53
19. Rahimtoola SH. Valvular heart disease: a perspective on the asymptomatic patient with severe valvular aortic stenosis. Eur Heart J 2008; 29: 1783-1790
20. Rodewald G, Kalmar P. Cardiac surgery in the Federal Republic of Germany during 1985. A report by the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surgeon 1986; 34: 406-408
21. Salem DN, Stein PD, Al-Ahmad A et al. Antithrombotic therapy in valvular heart disease - native and prosthetic. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126 (Suppl): 457S-482S
22. Vahanian A, Cormier B, Jung B. Percutaneous transvenous mitral commissurotomy using the Inoue Balloon: International Experience. Cath Cardiovasc Diagn 1994; Suppl 2: 8-15
23. Vahanian A, Baumgartner H, Bax J et al. Guidelines on the management of valvular heart disease. The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230-268
24. Villari B, Vassalli G, Monrad ES et al. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation 1995; 91: 2353-8
25. Weber KT. Cardiac interstitium in health and disease: The fibrillar collagen network. J Am Coll Cardiol 1989; 13: 1637-51